Topic: Prevention and Screening

Perioperative Pathways: What We Know Works

Peter Black, MD, FRCSC, provides an overview of the current Enhanced Recovery After Surgery (ERAS) protocol in the setting of radical cystectomy, recommendations from the ERAS Society, and how the practice increases bladder cancer patients’ quality of life. He also touches upon the possibility of adding alvimopan to ERAS protocol in the near future.

Read More

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guidelines

Sam Chang, MD, MBA, who has served as chair of the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), provides an overview of updated non-metastatic MIBC treatment guidelines, including a comprehensive treatment algorithm. He also discusses directions of future research for the disease.

Read More

Enhanced Techniques of Non-Muscle Invasive Bladder Cancer Detection

Michael S. Cookson, MD, describes the components of a quality transurethral resection of bladder tumor (TURBT), enhanced detection technologies such as blue light cystoscopy and narrow band imaging (NBI), and the induction of these new technologies into the American Urological Association (AUA) and Society of Urologic Oncology (SUO) bladder cancer guidelines and common practice.

Read More

Urine Markers for Bladder Cancer

Peter Black, MD, FRCSC, discusses the benefits and limitations of the currently FDA approved urinary biomarkers for bladder cancer. He defines criteria for the ideal biomarker, which would reduce the need for other diagnostic tests, have a high sensitivity and specificity rate, and be cost-effective for patients, as well as the possibility of using biomarkers in place of cystoscopy.

Read More
Loading

Join the GRU Community

- Why Join? -